Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News

OCTOBER 18, 2016

Domain Therapeutics and Medicxi launch Mavalon Therapeutics

Learn more... 

SEPTEMBER 28, 2016

Domain will present at  BIO Europe Congress on November 7-9, 2016 in Cologne, Germany (USA).

Domain Therapeutics’ presentation (Oncology category) is scheduled for 




    November 8, 2016




    Rheinsaal 4 on level 2

Lear more...

SEPTEMBER 27, 2016

Domain Therapeutics signed an exclusive license with universities of Montreal and McGill

Learn more... 

SEPTEMBER 22, 2016

Prexton Therapeutics completes phase 1 clinical trial with PXT002331

Learn more...